Common questions about Eskata (FAQ)
Q: Is Eskata a type of acid or a different kind of medicine?
Eskata is formally classified as a dermatologic agent whose active ingredient, hydrogen peroxide, functions as an oxidizing agent. Its pharmacological activity is defined by the generation of Reactive Oxygen Species (ROS), which leads to the targeted cellular damage described in official documents. It is therefore not chemically classified as an acid.
Q: What is the typical experience during and right after the treatment?
According to official product information, local reactions such as stinging or burning and visible signs like redness (erythema) and swelling (edema) are frequently observed during the application process. The provider monitors these effects during the short intervals between applications.
Q: Do I need to change my skincare routine before using Eskata?
Official administration guidelines describe the necessary preparation, which includes the healthcare provider clearing the lesion surface of oil and debris, often using an alcohol wipe, immediately before the treatment. The regulatory label does not include any specific instructions regarding general skincare routine changes leading up to the procedure.
Q: How long does the tingling or discomfort last after the session is over?
The most common immediate effects, such as stinging and swelling, are typically observed in the minutes immediately following the application. Other frequently observed skin reactions, such as scaling and crusting, are typically noted around one week following the treatment session.
Q: Is Eskata considered a cosmetic treatment?
Eskata is a prescription medicine that received regulatory approval for the treatment of raised seborrheic keratoses (SKs), which are benign lesions. The official labeling defines the drug by its medical indication for this condition.
Q: Do the official studies cover long-term outcomes of the treatment?
The pivotal clinical trials assessed the main outcome of complete clearance approximately 106 days after the initial treatment. Local skin reactions were officially monitored for up to 15 weeks after the initial session. The clinical trials measured outcomes within these specified timeframes.
Q: What are the signs that a spot is reacting properly to Eskata?
Administration documents state that whitening of the lesion may occur and is monitored by the provider during application. Following treatment, common documented reactions include redness, swelling, scaling, and crusting.
Q: Is it true that patients with a history of cold sores cannot use Eskata?
Regulatory documents list Herpes Zoster (shingles) as a less common adverse reaction observed in clinical trials. However, a history of Herpes Simplex (cold sores) is not listed as a formal restriction or contraindication in the official eligibility criteria.
Q: Can Eskata be used on all skin tones and types?
Regulatory documents do not specify limitations on use based on skin tone or type. However, official safety data indicates that local adverse reactions observed included changes in skin color, specifically hyperpigmentation (darkening) and hypopigmentation (lightening).
Q: How long is the applicator brush meant to be in contact with the lesion?
The administration instruction describes the need to apply the solution to uniformly wet the entire surface of the lesion, including the edges, while avoiding excess running or dripping. The protocol involves four applications repeated approximately one minute apart.
Q: Why might a healthcare provider choose Eskata over other options?
Eskata is described in regulatory information as the first and only FDA-approved topical solution for the non-invasive treatment of raised seborrheic keratoses. This approach is described as a non-invasive, topical method, which is distinct from physical removal methods.
Q: What is the ingredient that makes Eskata a solution?
The active component, hydrogen peroxide, is present in an aqueous solution, meaning water is the primary solvent. The full composition and a complete list of inactive ingredients (excipients) can be found in the regulatory description for the product.
Q: Is Eskata used by dermatologists or general practitioners?
The drug must be administered only by a healthcare provider in an in-office setting because it is a high-concentration prescription medicine. The official regulatory label does not restrict administration to a specific medical specialty.
Q: What happens if Eskata gets on the healthy skin around the spot?
The administration protocol instructs the healthcare provider to minimize the drug's contact with the surrounding healthy skin. If excess solution is present on the surrounding area, the protocol instructs the provider to remove it immediately with a clean absorbent wipe.
Q: Does the treatment require any kind of anesthesia or numbing cream?
The official administration instructions for the procedure are detailed and do not mention the use of local anesthesia or numbing agents as part of the standard protocol. The treatment is known to involve a stinging sensation.
Q: Does Eskata have a black box warning?
The official FDA Prescribing Information for Eskata does not include a Boxed Warning, which is often referred to as a 'Black Box Warning.' The product does, however, carry important warnings regarding the risk of serious eye injury.
